On October 1st Concit Pharma and Neurobiological Research Unit, Copenhagen National Hospital (Rigshospitalet) has initiated a research project supported by The Danish National Advanced Technology Foundation. The project will during the next two years focus on identification and characterization of new drugs for treatment of L-DOPA induced dysinesia.
Concit Pharma and Copenhagen University starts joint project
Latest news
-
Lundbeck and Contera Pharma
Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) and Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions, where significant unmet medical...
-
CP-012: Positive topline results in Phase 1b trial
Contera Pharma announces positive topline results in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease Hørsholm, September 17, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced positive topline results in a Phase 1b pharmacoscintigraphic study evaluating CP-012....
-
Last patient dosed in Phase 1b trial of CP-012
Contera Pharma announces last patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal symptoms and morning akinesia in Parkinson’s disease Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the last patient has been dosed in its Phase 1b...